Synonyms: NTP-42
Compound class:
Synthetic organic
Comment: NTP42 is a thromboxane receptor antagonist [3-4]. Its chemical structure is claimed in patent WO2016203314A1 [2]. TP signalling has demonstrable importance in the development and progression of pulmonary arterial hypertension (PAH). ATXA Therapeutics are progressing NTP42 into early stage clinical evaluation.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. EMA.
Orphan designation: NTP42. Accessed on 11/05/2021. Modified on 11/05/2021. www.ema.europa.eu, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181982 |
2. Kinsella BT, Reid H. (2016)
Thromboxane receptor antagonists. Patent number: WO2016203314A1. Assignee: University College Dublin, National University Of Ireland, Dublin. Priority date: 16/06/2015. Publication date: 22/12/2016. |
3. Mulvaney EP, Reid HM, Bialesova L, Bouchard A, Salvail D, Kinsella BT. (2020)
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension. BMC Pulm Med, 20 (1): 85. [PMID:32252727] |
4. Mulvaney EP, Reid HM, Bialesova L, Mendes-Ferreira P, Adão R, Brás-Silva C, Kinsella BT. (2020)
Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. Eur J Pharmacol, 889: 173658. [PMID:33121950] |